AstraZeneca Gets Rare Sell as Deutsche Bank Has Pipeline Worries

AstraZeneca Plc got a rare sell rating on Thursday as Deutsche Bank AG analysts downgraded the British drugmaker, taking a more skeptical view on the company’s drug pipeline, in particular for breast cancer treatments....

Redirecting to full article...